TheraRadar
← Back
Data updated: Mar 29, 2026

JAZZ PHARMS

OncologyRespiratoryGastroenterology
Specialty

JAZZ PHARMS is a specialty pharmaceutical company focused on Oncology, Respiratory, Gastroenterology. Key products include DEFITELIO.

2002
Since
5
Drugs
-
Trials
6
Approved (2yr)

Key Drugs

DEFITELIO
defibrotide sodium
Plasmin 4 indications · 2016

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Competitive Matchups Pro

Loading...

Recent Activity

XYREM 2025-07-28
REMS
XYREM 2025-05-21
REMS
ZIIHERA 2024-11-20
Type 1 - New Molecular Entity
XYREM 2024-11-18
REMS
XYREM 2024-05-22
REMS
RYLAZE 2024-04-15
Labeling
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 50%
2 drugs
Respiratory 25%
1 drugs
Gastroenterology 25%
1 drugs

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Pfizer big-pharma
Oncology, Gastroenterology
Gilead Sciences biotech
Oncology, Gastroenterology, Respiratory
Novartis big-pharma
Oncology, Respiratory
GSK big-pharma
Respiratory, Oncology
Sanofi big-pharma
Oncology, Respiratory